# Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study

> **NCT07210528** · PHASE1 · RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 48 (estimated)

## Conditions studied

- Mild Cognitive Impairment (MCI)
- Alzheimer Dementia (AD)

## Interventions

- **DRUG:** Emtricitabine (FTC)
- **DRUG:** Descovy® (TAF/FTC)
- **DRUG:** Placebo to Match Emtricitabine 200mg/Tenofovir Alafenamide 25 mg.
- **DRUG:** Placebo Capsules to Match Emtricitabine Capsules, 200mg.

## Key facts

- **NCT ID:** NCT07210528
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2026-03
- **Final completion:** 2026-04
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07210528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07210528, "Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07210528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*